A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
NDA filed for Xcytrin and with Fast Track status should have a response from the FDA by June 2007. Insider buying activity is very bullish indicating they think they'll get approval. Company owns 100% of all North America revenue with expectations of capturing 50% of the 150K cases per year for Brain Mets in the US. Comparing to other companies rev/patient might bring $14K. Do that math and this could get very interesting as the year goes by.
... the insider buying is not real insider, but a benefial owner, which happens to be a company called Robert W Duggan, check http://www.dugganassociates.com
Now...the problem is, most of these money management companies don't beat the markets, specially the ones focusing in small stocks. I checked what they said in the page and they "predict future prices"... well, and I say, they can do that because nobody else can.
Robbert W Duggan sells bad funds and invest in stocks in a way that will yield random results.
I regret having picked this company, I think it's time to lick my wounds and close it.